Table 1.
Clinical, auxological and hormonal data of 53 patients with CAH.
| SW patients | SV patients | |
| Female/Male | 27/11 | 11/4 |
| Age at diagnosis (y) | 0.2±0.8 | 2.9±1.7 |
| Mean bone age (y) at diagnosis | - | 5.8±4.5 |
| Basal 17OHP (mmol/L) levels at diagnosis | 303±341 | 199±166 |
| Mean daily CA doses (mg/m2/day) | 18.5±3.4 | 20.1±3.3 |
| Fludrocortisone ( µg/day) | 50±25 | - |
| Mean BMI at 4 y (kg/m2) | 17.1±2.1 | 16.2±1.3 |
| Mean BMI at 6 y (kg/m2) | 16.2±1.6 | 17.6±2.7 |
| Mean BMI at 4 y (SDU)1 | 1.0±0.9 | 0.6±0.8 |
| Mean BMI at 6 y (SDU)1 | 1.0±1.1 | 0.4±0.8 |
| Height SDS for bone age at 4 y | 0.02 | 0.9 |
| Height SDS for bone age at 6 y | 0.16 | 1.3 |
| Final height SDS** | −1.4±1.4 | −1.0±0.9 |
| Target height SDS | −0.9±1.0 | −0.6±1.2 |
SW: salt-wasting form, SV: simple virilizing form, CA: cortisone acetate dose used from 4–6 y of age.
Values are presented as the mean±SD.
**
13/53 patients achieved final height.
1SDU scores are the number of SD units relative to the mean values for normal children of the same age and sex.